ORDIN DE PLATA NR.: 961 TIP.DOC. 1

DATA EMITERII:21 octombrie 2021

PLATITI: 5000-00 LEI: Cinci Mii lei 00 bani

PLATITOR: (R) "BIOSISTEM MLD" S.R.L.
CONTUL DE PLATI/CODUL IBAN
MD95ML0000000022514292 43
CODUL FISCAL :1010600028048 /

PRESTATORUL PLATITOR
BC"Moldindconbank"S.A. fil."Invest" Chisinau
CODUL BANCII:
:MOLDMD2X329:

BENEFICIAR (R) Centrul pentru achizitii publice centralizate in sanatate
CONTUL DE PLATI/CODUL IBAN
MD23TRPCCC518430B01859AA
CODUL FISCAL :1016601000212 /

PRESTATORUL BENEFICIAR
Ministerul Finantelor - Trezoreria de Stat
CODUL BANCII:
:TREZMD2X :

DESTINATIA PLATII:/P102/5000,00 Pentru garantia pentru oferta la procedura de achizi?ie publica nr. ocds-b3wdp1-MD-16292 75333205 din 23.10.2021

TIPUL TRANSFERULUI
NORMAL/URGENT :N:

L.S.

CODUL TRANZACTIEI:101:
DATA PRIMIRII:21/10/2021
DATA EXECUTARII:
SEMNATURILE EMITENTULUI

CONDUCATOR:Web Poiata Vitalie

MIIGYwYJKoZIhvcNAQcCoIIGVDCCBlACAQExCzAJBgUrDgMCGgUAMAsGCSqGSIb3DQEHAaCCBGwwggRoMIIDUKADAgECAhNHAACjbi1rgFksQ0G4AAAAKNuMA0GCSqSIb3DQEBCwUAMCIxIDAeBgNVBAMTF0NFUlQxLUNBLU1vbGRpbmRjb25iYW5rMB4XDTIxMDEyODExMzgwNVoXDTI0MDEyODExNDgwNVowgZ8xCzAJBgNVBAYTAk1EMRAwDgYDVQQIEwdNb2xkb3ZhMREwDwYDVQQHEwhDaGlzaW5hdTEWMBQGA1UEChMNQml

(semnatura electronica)

CONTABIL-SEF:Web Nasedchin Alexandr

MIIGZwYJKoZIhvcNAQcCoIIGWDCCBlQCAQExCzAJBgUrDgMCGgUAMAsGCSqGSIb3DQEHAaCCBHAwggRsMIIDVKADAgECAhNHAACjcahRKqbJeg8QAAAAAKNxMA0GCSqGSIb3DQEBCwUAMCIxIDAeBgNVBAMTF0NFUlQxLUNBLU1vbGRpbmRjb25iYW5rMB4XDTIxMDEyODExMzkxOFoXDTI0MDEyODExNDkxOFowgaMxCzAJBgNVBAYTAk1EMRAwDgYDVQQIEwdNb2xkb3ZhMREwDwYDVQQHEwhDaGlzaW5hdTEWMBQGA1UEChMNQml

L.S. (semnatura electronica)

CONDUCATOR: _____
(semnatura manuala)

CONTABIL-SEF: _____
(semnatura manuala)

SEMNATURA PRESTATORUL L.S.

MOTIVUL REFUZULUI L.S.

Digitally signed by Poiata Vitalie
Date: 2021.10.22 13:58:05 EEST
Reason: MoldSign Signature
Location: Moldova

Anexa nr.7.2 la Instrucţiunea
aprobată prin ordinul IFPS
nr. 400 din 14 martie 2014

CC 04 AE

CERTIFICAT
privind lipsa sau existenţa restanţelor faţă de bugetul public naţional

Nr. / № A2117863 **din** / от 21.10.2021

1. Destinaţia / Назначение

Pentru participare de proceduri de achizitii publice

2. Date despre contribuabil / Информация о налогоплательщике

Denumirea Наименование	**Codul fiscal / Numărul de identificare** Фискальный код / Идентификационный номер
BIOSISTEM MLD S.R.L.	1010600028048
Adresa sediului de bază (strada, numărul) Адрес основного месторасположения (улица, номер)	**Codul - Denumirea localităţii** Код - Наименование населенного пункта
Albisoara nr.16 bl.1 of.7	0150-SEC.RISCANI

3. Atestarea lipsei sau existenţei restanţelor conform datelor Sistemului Informaţional Automatizat / Подтверждение отсутствия или наличия недоимки согласно данных Информационной автоматизированной системы

La data emiterii prezentului certificat restanţa faţă de bugetul public naţional constituie/ На дату выдачи данной справки недоимка перед национальным публичным бюджетом составляет: **0,00** lei/лей.

4. Valabil pînă la / Действителен до 05.11.2021

5. Autentificarea Serviciului Fiscal de Stat / Подтверждение Государственной налоговой службы

Şef DDF Rîşcani
a DGAF mun. Chişinău
Funcţia/Должность

Semnătura/Подпись

Viorica CĂUŞ
Numele şi prenumele/Фамилия и имя

L.Ş/ M.П.

Executor: *Svetlana Slonovscaia*
Numele şi prenumele/Фамилия и имя

Este extras din Sistemul Informaţional al SFS SIA „Contul curent al contribuabilului"// 21.10.2021 ora 9:27:23
cu aplicarea prevederilor pct. 82-83 Ordin IFPS nr.400 din 14.03.2014 (Monitorul Oficial 72-77/399, 28.03.2014)

NOTA (3,52)

BC "MOLDINDCONBANK" S.A.
Filiala "Invest"

Republica Moldova, MD-2068
mun. Chişinău, bd. Moscovei, 14/1
Tel. : (373-22) 43-44-81, 43-46-24
Fax : (373-22) 43-44-22
cod: MOLDMD2X329

Data 14. IAN. 2016
Nr. 03/2 – 19/23

Республика Молдова, MD-2068
мун. Кишинэу, бул. Московей, 14/1
Тел. : (373-22) 43-44-81, 43-46-24
Факс : (373-22) 43-44-22
код: MOLDMD2X329

Filiala „Invest" BC „Moldindconbank" SA confirmă existența contului curent in moneda nationala al **"BIOSISTEM MLD" S.R.L. (c/f 1010600028048)**, cu **IBAN MD95ML0000000022514292 43**.

Codul băncii MOLDMD2X329.

Director **Nina Țurcan**

Director financiar **Nina Balmuş**

Ex. Diana Brinza
Tel. 43-45-96

REPUBLICA MOLDOVA

CERTIFICAT DE ÎNREGISTRARE

Societatea cu Răspundere Limitată "BIOSISTEM MLD"
ESTE ÎNREGISTRATĂ LA CAMERA ÎNREGISTRĂRII DE STAT

Numărul de identificare de stat - codul fiscal
1010600028048

Data înregistrării **12.08.2010**

Data eliberării **12.08.2010**

Svirepova Ludmila, registrator

Funcția, numele, prenumele persoanei care a eliberat certificatul

semnătura

MINISTERUL JUSTIȚIEI AL REPUBLICII MOLDOVA
CAMERA ÎNREGISTRĂRII DE STAT I.S.
1004600077777
104

MD 0101250

I.P. "AGENŢIA SERVICII PUBLICE"

Departamentul înregistrare şi licenţiere a unităţilor de drept

EXTRAS

din Registrul de stat al persoanelor juridice

nr. **8506** din **28.04.2021**

Denumirea completă: **Societatea cu Răspundere Limitată «BIOSISTEM MLD».**

Denumirea prescurtată: **«BIOSISTEM MLD» S.R.L.**

Forma juridică de organizare: **Societate cu Răspundere Limitată.**

Numărul de identificare de stat şi codul fiscal: **1010600028048.**

Data înregistrării de stat: **12.08.2010.**

Sediul: **MD-2001, str. Albişoara, 16/1, ap.(of.) 7, mun. Chişinău, Republica Moldova.**

Obiectul principal de activitate:

1 Activitatea farmaceutică;

2 Importul, fabricarea, comercializarea, asistenţa tehnică şi (sau) reparaţia dispozitivelor medicale şi (sau) a opticii;

3 Acordarea asistenţei medicale de către instituţiile medico-sanitare private;

4 Comerţul cu ridicata al calculatoarelor, echipamentelor periferice şi software-ului;

5 Întreţinerea şi repararea maşinilor de birou şi a tehnicii de calcul;

6 Consultaţii în domeniul sistemelor de calcul.

Capitalul social: **5400** lei.

Administrator: POIATA VITALIE,

Asociaţi:

1. POIATA VITALIE 33,40 %

2. NASEDCHIN ALEXANDR 33,30 %

3. KOJEVNIKOV DMITRII 33,30 %.

Prezentul extras este eliberat în temeiul art. 34 al Legii nr. 220-XVI din 19 octombrie 2007 privind înregistrarea de stat a persoanelor juridice şi a întreprinzătorilor individuali şi confirmă datele din Registrul de stat la data de: 28.04.2021.

Specialist coordonator
tel. 022-207-840

Lazari Aliona

"AGENŢIA SERVICII PUBLICE" IDNO 1002600024700 REPUBLICA MOLDOVA CHIŞINĂU 003

EB 0358735

BIOSISTEM-MLD S.R.L.
c/f 1010600028048; adresa: or. Chișinău, str. Albișoara 16/1 of.7
tel.+373-22-808-517, +373-22-808719, fax: +373-22-808-519.
Web: www.biosistem-mld.com; e-mail: biosistem.mld@gmail.com

Lista fondatorilor Biosistem-mld SRL

Nr.	Nume, Prenume	IDNP
1.	Vitalie Poiata	0983103892591
2.	Alexandr Nasedchin	2002001070747
3.	Dmitrii Kojevnikov	0972305012362

Дата предоставления 11.05.2021 10:00:47

Anexe la SNC
"Prezentarea situațiilor financiare"
Aprobat de Ministerul Finanțelor
al Republicii Moldova

SITUAȚIILE FINANCIARE

pentru perioada 01.01.2020 - 31.12.2020

Entitatea: BIOSISTEM MLD S.R.L.
Cod CUIÎO: 40717392
Cod IDNO: 1010600028048

Sediul:
MD:
Raionul(municipiul): 106, DDF RISCANI
Cod CUATM: 0150, SEC.RISCANI
Strada: SECTORUL RISCANI STR.Albisoara nr.16 bl.1 of.7

Activitatea principală: G4646, Comert cu ridicata al produselor farmaceutice
Forma de proprietate: 16, Proprietate colectivă
Forma organizatorico-juridică: 530, Societăți cu răspundere limitată

Date de contact:
Telefon: +37322808719
WEB:
E-mail: zmii13@mail.ru
Numele și coordonatele al contabilului-șef: Dl (dna) Tel.

Numărul mediu al salariaților în perioada de gestiune: 3 **persoane.**

Persoanele responsabile de semnarea situațiilor financiare* Nasedchin Alexandr

Unitatea de măsură: leu

BILANȚUL

la

Anexa 1

Nr. cpt.	Indicatori	Cod rd.	Sold la	
			Începutul perioadei de gestiune	Sfîrșitul perioadei de gestiune
1	2	3	4	5
	A C T I V			
	ACTIVE IMOBILIZATE			
	I. Imobilizări necorporale			
	1. Imobilizări necorporale în curs de execuție	010		
	2. Imobilizări necorporale în exploatare, total	020	487	
	din care: 2.1. concesiuni, licențe și mărci	021	487	
	2.2. drepturi de autor și titluri de protecție	022		
	2.3. programe informatice	023		
	2.4. alte imobilizări necorporale	024		
	3. Fond comercial	030		
	4. Avansuri acordate pentru imobilizări necorporale	040		
	Total imobilizări necorporale (rd.010 + rd.020 + rd.030 + rd.040)	050	487	
	II. Imobilizări corporale			
	1. Imobilizări corporale în curs de execuție	060		
	2. Terenuri	070		
	3. Mijloace fixe, total	080	2208593	2793637
	din care: 3.1. clădiri	081		
	3.2. construcții speciale	082		
	3.3. mașini, utilaje și instalații tehnice	083	2204135	2791637
	3.4. mijloace de transport	084		
	3.5. inventar și mobilier	085		
	3.6. alte mijloace fixe	086	4458	2000
A.	4. Resurse minerale	090		
	5. Active biologice imobilizate	100		
	6. Investiții imobiliare	110		
	7. Avansuri acordate pentru imobilizări corporale	120		
	Total imobilizări corporale (rd.060 + rd.070 + rd.080 + rd.090 + rd.100 + rd.110 + rd.120)	130	2208593	2793637
	III. Investiții financiare pe termen lung			
	1. Investiții financiare pe termen lung în părți neafiliate	140		
	2. Investiții financiare pe termen lung în părți afiliate, total	150		
	din care: 2.1. acțiuni și cote de participație deținute în părțile afiliate	151		
	2.2 Împrumuturi acordate părților afiliate	152		
	2.3 Împrumuturi acordate aferente intereselor de participare	153		
	2.4 alte investiții financiare	154		
	Total investiții financiare pe termen lung (rd.140 + rd.150)	160		
	IV. Creanțe pe termen lung și alte active imobilizate			
	1. Creanțe comerciale pe termen lung	170		
	2. Creanțe ale părților afiliate pe termen lung	180		
	inclusiv: creanțe aferente intereselor de participare	181		
	3. Alte creanțe pe termen lung	190		
	4. Cheltuieli anticipate pe termen lung	200		
	5. Alte active imobilizate	210		
	Total creanțe pe termen lung și alte active imobilizate (rd.170 + rd.180 + rd.190 + rd.200 + rd.210)	220		
	TOTAL ACTIVE IMOBILIZATE (rd.050 + rd.130 + rd.160 + rd.220)	230	2209080	2793637
	ACTIVE CIRCULANTE			
	I. Stocuri			
	1. Materiale și obiecte de mică valoare și scurtă durată	240	54051	51978
	2. Active biologice circulante	250		
	3. Producția în curs de execuție	260		
	4. Produse și mărfuri	270	5710647	7221203
	5. Avansuri acordate pentru stocuri	280		
	Total stocuri (rd.240 + rd.250 + rd.260 + rd.270 + rd.280)	290	5764698	7273181
	II. Creanțe curente și alte active circulante			
	1. Creanțe comerciale curente	300	4337729	3912218
	2. Creanțe ale părților afiliate curente	310		
	inclusiv: creanțe aferente intereselor de participare	311		
	3. Creanțe ale bugetului	320	166486	74631
	4. Creanțele ale personalului	330		
	5. Alte creanțe curente	340		
	6. Cheltuieli anticipate curente	350	4	2
B.	7. Alte active circulante	360	1647908	5756117
	Total creanțe curente și alte active circulante (rd.300 + rd.310 + rd.320 + rd.330 + rd.340 + rd.350 + rd.360)	370	6152127	9742968
	III. Investiții financiare curente			
	1. Investiții financiare curente în părți neafiliate	380		
	2. Investiții financiare curente în părți afiliate, total	390		
	din care: 2.1. acțiuni și cote de participație deținute în părțile afiliate	391		
	2.2. Împrumuturi acordate părților afiliate	392		
	2.3. Împrumuturi acordate aferente intereselor de participare	393		
	2.4. alte investiții financiare în părți afiliate	394		
	Total investiții financiare curente (rd.380 + rd.390)	400		
	IV. Numerar și documente bănești	410	8911899	3942779
	TOTAL ACTIVE CIRCULANTE (rd.290 + rd.370 + rd.400 + rd.410)	420	20828724	20958928
	TOTAL ACTIVE (rd.230 + rd.420)	430	23037804	23752565
	P A S I V			
	CAPITAL PROPRIU			
	I. Capital social și neînregistrat			
	1. Capital social	440	5400	5400
	2. Capital nevărsat	450	( )	( )
	3. Capital nelnregistrat	460		
	4. Capital retras	470	( )	( )
	5. Patrimoniul primit de la stat cu drept de proprietate	480		
	Total capital social și neînregistrat (rd.440 + rd.450 + rd.460 + rd.470 + rd.480)	490	5400	5400
	II. Prime de capital	500		
	III. Rezerve			
	1. Capital de rezervă	510		
	2. Rezerve statutare	520		
	3. Alte rezerve	530		
C.	**Total rezerve** (rd.510 + rd.520 + rd.530)	540		
	IV. Profit (pierdere)			
	1. Corecții ale rezultatelor anilor precedenți	550	X	
	2. Profit nerepartizat (pierdere neacoperită) al anilor precedenți	560	21021465	12085295
	3. Profit net (pierdere netă) al perioadei de gestiune	570	X	7974831
	4. Profit utilizat al perioadei de gestiune	580	X	( )
	Total profit (pierdere) (rd.550 + rd.560 + rd.570 + rd.580)	590	21021465	20060126
	V. Rezerve din reevaluare	600		
	VI. Alte elemente de capital propriu	610		
	TOTAL CAPITAL PROPRIU (rd.490 + rd.500 + rd.540 + rd.590 + rd.600 + rd.610)	620	21026865	20065526
	DATORII PE TERMEN LUNG			
	1. Credite bancare pe termen lung	630		
	2. Împrumuturi pe termen lung	640		
	din care: 2.1. Împrumuturi din emisiunea de obligațiuni	641		
	inclusiv: Împrumuturi din emisiunea de obligațiuni convertibile	642		
	2.2. alte împrumuturi pe termen lung	643		
D.	3. Datorii comerciale pe termen lung	650		
	4. Datorii față de părțile afiliate pe termen lung	660		
	inclusiv: datorii aferente intereselor de participare	661		
	5. Avansuri primite pe termen lung	670		
	6. Venituri anticipate pe termen lung	680		
	7. Alte datorii pe termen lung	690		
	TOTAL DATORII PE TERMEN LUNG (rd.630 + rd.640 + rd.650 + rd.660 + rd.670 + rd.680 + rd.690)	700		
	DATORII CURENTE			
	1. Credite bancare pe termen scurt	710		
	2. Împrumuturi pe termen scurt, total	720		
	din care: 2.1. Împrumuturi din emisiunea de obligațiuni	721		
	inclusiv: Împrumuturi din emisiunea de obligațiuni convertibile	722		
	2.2. alte împrumuturi pe termen scurt	723		
	3. Datorii comerciale curente	730	1331928	3252667
	4. Datorii față de părțile afiliate curente	740		
E.	inclusiv: datorii aferente intereselor de participare	741		
	5. Avansuri primite curente	750	159545	188105
	6. Datorii față de personal	760	2913	50
	7. Datorii privind asigurările sociale și medicale	770		
	8. Datorii față de buget	780	434590	187676
	9. Datorii față de proprietari	790		
	10. Venituri anticipate curente	800		
	11. Alte datorii curente	810	81963	58541
	TOTAL DATORII CURENTE (rd.710 + rd.720 + rd.730 + rd.740 + rd.750 + rd.760 + rd.770 + rd.780 + rd.790 + rd.800 + rd.810)	820	2010939	3687039
	PROVIZIOANE			
	1. Provizioane pentru beneficiile angajaților	830		
	2. Provizioane pentru garanții acordate cumpărătorilor/clienților	840		
F.	3. Provizioane pentru impozite	850		
	4. Alte provizioane	860		
	TOTAL PROVIZIOANE (rd.830 + rd.840 + rd.850 + rd.860)	870		
	TOTAL PASIVE (rd.620 + rd.700 + rd.820 + rd.870)	880	23037804	23752565

SITUAȚIA DE PROFIT ȘI PIERDERE

de la pînă la

Anexa 2

Indicatori	Cod rd.	Perioada de gestiune	
		precedenta	curenta
1	2	3	4
Venituri din vînzări, total	010	27319617	25963175
din care: venituri din vînzarea produselor și mărfurilor	011	26856566	25044358
venituri din prestarea serviciilor și executarea lucrărilor	012	463051	918817
venituri din contracte de construcție	013		
venituri din contracte de leasing	014		
venituri din contracte de microfinanțare	015		
alte venituri din vînzări	016		
Costul vînzărilor, total	020	15672962	15186814
din care: valoarea contabilă a produselor și mărfurilor vîndute	021	15672962	15186814
costul serviciilor prestate și lucrărilor executate terților	022		
costuri aferente contractelor de construcție	023		
costuri aferente contractelor de leasing	024		
costuri aferente contractelor de microfinanțare	025		
alte costuri aferente vînzărilor	026		
Profit brut (pierdere brută) (rd.010 - rd.020)	030	11646655	10776361
Alte venituri din activitatea operațională	040	28586	247603
Cheltuieli de distribuire	050	16306	19740
Cheltuieli administrative	060	964136	1259776
Alte cheltuieli din activitatea operațională	070	417394	640169
Rezultatul din activitatea operațională: profit (pierdere) (rd.030 + rd.040 - rd.050 - rd.060 - rd.070)	080	10277405	9104279

Venituri financiare, total	090	490609	519239
din care: venituri din interese de participare	091		
inclusiv: veniturile obținute de la părțile afiliate	092		
venituri din dobînzi	093		25612
inclusiv: veniturile obținute de la părțile afiliate	094		
venituri din alte investiții financiare pe termen lung	095		
inclusiv: veniturile obținute de la părțile afiliate	096		
venituri aferente ajustărilor de valoare privind investițiile financiare pe termen lung și curente	097		
venituri din ieșirea investițiilor financiare	098		
venituri aferente diferențelor de curs valutar și de sumă	099	490609	493627
Cheltuieli financiare, total	100	686605	597528
din care: cheltuieli privind dobînzile	101		
inclusiv: cheltuielile aferente părților afiliate	102		
cheltuieli aferente ajustărilor de valoare privind investițiile financiare pe termen lung și curente	103		
cheltuieli aferente ieșirii investițiilor financiare	104		
cheltuieli aferente diferențelor de curs valutar și de sumă	105	686605	597528
Rezultatul: profit (pierdere) financiar(ă) (rd.090 - rd.100)	110	-195996	-78289
Venituri cu active imobilizate și excepționale	120		
Cheltuieli cu active imobilizate și excepționale	130		
Rezultatul din operațiuni cu active imobilizate și excepționale: profit (pierdere) (rd.120 - rd.130)	140		
Rezultatul din alte activități: profit (pierdere) (rd.110 + rd.140)	150	-195996	-78289
Profit (pierdere) pînă la impozitare (rd.080 + rd.150)	160	10081409	9025990
Cheltuieli privind impozitul pe venit	170	1178993	1051159
Profit net (pierdere netă) al perioadei de gestiune (rd.160 - rd.170)	180	8902416	7974831

SITUAȚIA MODIFICĂRILOR CAPITALULUI PROPRIU

de la pînă la

Anexa 3

Nr. d/o	Indicatori	Cod rd	Sold la începutul perioadei de gestiune	Majorări	Diminuări	Sold la sfîrșitul perioadei de gestiune
1	2	3	4	5	6	7
I.	**Capital social și neînregistrat**					
	1. Capital social	010				
	2. Capital nevărsat	020	( )	( )	( )	( )
	3. Capital neînregistrat	030				
	4. Capital retras	040	( )	( )	( )	( )
	5. Patrimoniul primit de la stat cu drept de proprietate	050				
	Total capital social și neînregistrat (rd.010 + rd.020 + rd.030 + rd.040 + rd.050)	060				
II.	**Prime de capital**	070				
III.	**Rezerve**					
	1. Capital de rezervă	080				
	2. Rezerve statutare	090				
	3. Alte rezerve	100				
	Total rezerve (rd.080 + rd.090 + rd.100)	110				
IV.	**Profit (pierdere)**					
	1. Corecții ale rezultatelor anilor precedenți	120	X			
	2. Profit nerepartizat (pierdere neacoperită) al anilor precedenți	130				
	3. Profit net (pierdere netă) al perioadei de gestiune	140	X			
	4. Profit utilizat al perioadei de gestiune	150	X	( )	( )	( )
	Total profit (pierdere) (rd.120 + rd.130 + rd.140 + rd.150)	160				
V.	**Rezerve din reevaluare**	170				
VI.	**Alte elemente de capital propriu**	180				
	Total capital propriu (rd.060 + rd.070 + rd.110 + rd.160 + rd.170 + rd.180)	190				

SITUAȚIA FLUXURILOR DE NUMERAR

de la pînă la

Anexa 4

Indicatori	Cod rd	Perioada de gestiune	
		precedentă	curentă
1	2	3	4
Fluxuri de numerar din activitatea operațională			
Încasări din vînzări	010		
Plăți pentru stocuri și servicii procurate	020		
Plăți către angajați și organe de asigurare socială și medicală	030		
Dobînzi plătite	040		
Plata impozitului pe venit	050		
Alte încasări	060		
Alte plăți	070		
Fluxul net de numerar din activitatea operațională (rd.010 - rd.020 - rd.030 - rd.040 - rd.050 + rd.060 - rd.070)	080		
Fluxuri de numerar din activitatea de investiții			
Încasări din vînzarea activelor imobilizate	090		
Plăți aferente intrărilor de active imobilizate	100		
Dobînzi încasate	110		
Dividende încasate	120		
inclusiv: dividende încasate din străinătate	121		
Alte încasări (plăți)	130		
Fluxul net de numerar din activitatea de investiții (rd.090 - rd.100 + rd.110 + rd.120 ± rd.130)	140		
Fluxuri de numerar din activitatea financiară			
Încasări sub formă de credite și împrumuturi	150		
Plăți aferente rambursării creditelor și împrumuturilor	160		
Dividende plătite	170		
inclusiv: dividende plătite nerezidenților	171		
Încasări din operațiuni de capital	180		
Alte încasări (plăți)	190		
Fluxul net de numerar din activitatea financiară (rd.150 - rd.160 - rd.170 + rd.180 ± rd.190)	200		
Fluxul net de numerar total (± rd.080 ± rd.140 ± rd.200)	210		
Diferențe de curs valutar favorabile (nefavorabile)	220		
Sold de numerar la începutul perioadei de gestiune	230		
Sold de numerar la sfîrșitul perioadei de gestiune (± rd.210 ± rd.220 + rd.230)	240		

Documente atașate - Notă explicativă (fișierul pdf)

Расписка 2

Респондент
Фискальный код: 1010600028048, наименование: BIOSISTEM MLD S.R.L.
Предоставил отчёт: RSF1_21
На фискальный период: A/2020
Дата предоставления: 11.05.2021
Временная метка отчёта зарегистрированного в Информационной Системе НБС : 11.05.2021 12:26:31

National Bureau of Statistics (NBS) received the electronic version of the report, sent by you. The data provided is verified by NBS.

Расписка

Респондент
Фискальный код: 1010600028048, наименование: BIOSISTEM MLD S.R.L.
Предоставил отчёт: RSF1_21
На фискальный период: A/2020
Дата предоставления: 11.05.2021
Временная метка отчёта зарегистрированного в Системе Электронной Отчётности и отправленного в Информационную Систему БНС : 11.05.2021 10:00:47

BIOSISTEM-MLD S.R.L.
c/f 1010600028048; adresa: str. Albișoara 16/1 of.7, or. Chișinău
tel.+373-22-808517, +373-22-808719, fax +373-22-808519.
Web: www.biosistem-mld.com; e-mail: biosistem.mld@gmail.com

Către Grupul de lucru pentru evaluarea
Procedurii de achiziție nr. ocds-b3wdp1-MD-1629275333205
Din 30 sept 2021, 9:46 - 23 oct 2021, 9:46
din cadrul CAPCS

Declarație

Prin prezenta, SRL „Biosistem-mld", declara ca :

- Va înregistra în Registrul de Stat al Dispozitivelor Medicale a Agenției Medicamentului și Dispozitivelor Medicale bunurile contractate pînă la momentul livrării acestora.
- Termenul de valabilitate restant (la momentul livrarii) va constitui minim 80% din termenul total al produsului, dar nu mai mic de 12 luni.
- Va prezenta mostre in termen de 5 zile de la solicitarea autoritatii contractante.
- Va garanta livrarea produselor la destinatar cu respectarea conditiilor de pastrare si transportare pe tot parcursul lantului de transportare de la fabricant la beneficiar.

_____Vitalie Poiata

L.Ș.

COD 31011 50 tests	COD 31311 100 tests	COD 31012 150 tests	COD 31107 50 tests
STORE AT 2-8ºC			
Reagents for determination of CRP Only for *in vitro* use in the clinical laboratory			

C-REACTIVE PROTEIN (CRP) - SLIDE

BioSystems
REAGENTS & INSTRUMENTS

CE

C-REACTIVE PROTEIN (CRP)
LATEX

PRINCIPLE OF THE METHOD

Serum C-reactive protein (CRP) at 6 mg/L or higher causes a visible agglutination on slide of a suspension of latex particles coated with anti-human C-reactive protein [1-2].

CONTENTS

	COD 31011	COD 31311	COD 31012	COD 31107
A. Reagent	1 x 3 mL	2 x 3 mL	1 x 8 mL	1 x 3 mL
C-. Negative Control	1 x 1 mL	1 x 1 mL	1 x 1 mL	-
C+. Positive Control	1 x 1 mL	1 x 1 mL	1 x 1 mL	-
Test Cards	3	6	6	-
Disposable stirrer sticks	1 x 50	1 x 150	1 x 150	-

COMPOSITION

A. Reagent: Suspension of latex particles coated with anti-human C-reactive protein, sodium azide 0.95 g/L, borate buffer 100 mmol/L, pH 8.2.

C–. Negative Control: Serum containing CRP < 6 mg/L.

C+. Positive Control: Human serum containing CRP > 6 mg/L.

Human sera used in the preparation of the positive and negative controls have been tested and found to be negative for the presence of antibodies anti-HIV and anti-HCV, as well as for HBs antigen. However, the controls should be handled cautiously as potentially infectious.

Test Cards.(Note 1)

Disposable stirrer sticks.

STORAGE

Store at 2-8ºC. Cards and stirrer sticks may be kept at room temperature.

Reagent and Controls are stable until the expiry date shown on the label when stored tightly closed and if contaminations are prevented during their use.

Indications of deterioration:

– Reagent: Visible agglutination in the flask.

– Controls: Presence of particulate material.

REAGENT PREPARATION

Reagent and controls are provided ready to use.

ADDITIONAL EQUIPMENT

– Mechanical rotator adjustable to 100 r.p.m.

– For code 31107 test cards and stirrer sticks will be required.

SAMPLES

Serum collected by standard procedures.

CRP in serum is stable for 7 days at 2-8ºC.

PROCEDURE

1. Bring test reagents and samples to room temperature (Note 2).
2. Place 50 µL of the sample and 1 drop of each Control into separate circles on the test card.
3. Shake the latex vial (A) gently repeatedly until complete resuspension of the latex particles. Hold the Reagent vial (A) in vertical position and add 1 drop of Reagent (A) to each circle next to the sample to be tested (Note 3).
4. Mix with a disposable stirrer stick and spread over the entire area enclosed by the ring. Use a new stirrer stick for each sample.
5. Rotate cards at 100 r.p.m. for 2 minutes.

READING

Examine the presence of visible agglutinantion within a minute after removing the card from the rotator (Note 4).

Positive results: The presence of a visible agglutination indicates an PCR concentration in the sample ≥ 6 mg/L. Positive sera may be titered. To titer make serial two-fold dilutions in 9 g/L NaCl. The serum titer is defined as the highest dilution showing a positive result. The approximate PCR concentration in the sample may be obtained by multiplying the titer by 6 mg/L.

Negative results: The absence of a visible agglutination indicates a content of CRP < 6 mg/L.

QUALITY CONTROL

Positive (C+) and Negative (C-) Controls provided with kits should be tested toghether with the patients samples, in order to verify the assay performance.

Positive Control (C+) should cause a clear visible agglutination of the latex particles.

Negative Control (C-) should not cause any agglutination of the latex particles.

Each laboratory should establish its own internal Quality Control scheme and procedures for corrective action if controls do not recover within the acceptable tolerances.

ASSAY CHARACTERISTICS

– Detectability: 6 mg/L CRP, using an internal standard traceable to the Standard Reference Material BCR 470 (Institute for Reference Materials and Measurements, IRMM). The cut off value may vary up to 25% depending on uncontrolled variations in the procedure and on the operator experience in reading.

– High dose (zone) effect: False negative results due to high dose effect are absent at least up to 250 mg/L.

– False results: Results obtained with this reagent did not show significative differences when compared with reference reagents. Details of the comparison experiments are available on request.

– Interferences: Hemoglobin (5 g/L), bilirubin (15 mg/dL) and lipemia (5 g/L) do not interfere. Rheumatoid factors may interfere (25 IU/mL). Other drugs and substances may interfere[3].

DIAGNOSTIC CHARACTERISTICS

C-Reactive Protein (CRP), which is synthesized in the liver, is one of the the most sensitive acute phase reactants after tissue damage or inflammation. CRP activates the classical complement pathway as a response to the inflammatory reaction.

CRP levels in plasma can rise dramatically after myocardial infarction, stress, trauma, infection, inflammation, surgery or neoplastic proliferation. The increase occurs within 24 to 48 hours and the level may be 2000 times normal. An elevation can be expected in virtually all diseases involving tissue damages so the finding is nonspecific[4-5].

Clinical diagnosis should not be made on the findings of a single test result, but should integrate both clinical and laboratory data.

NOTES

1. The test cards are reusable, and must be washed out and thoroughly rinsed with distilled water free of all detergents.
2. The sensitivity of the test may be reduced at low temperatures.
3. The presence of agglutinated particles at this point may be due to a lack of homogenization of the reagent.
4. Delay in reading may cause false positive results.

BIBLIOGRAPHY

1. Singer JM, Plotz CM, Pader E, Elster SK. The latex-fixation test. III. Agglutination test for c-reactive protein and comparison with the capillary precipitin method. *Am J Clin Pathol 1957; 28:611*.
2. Hokama Y, Nakamura RM. C-reactive protein: current status and future perspectives. *J Clin Anal* 1987; 1: 15-27.
3. Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000.
4. Friedman and Young. Effects of disease on clinical laboratory tests, 4th ed. AACC Press, 2001.
5. Immunology and Serology in Laboratory Medicine, 2nd edition. Turgeon ML. Mosby, 1996.

COD 31013 50 tests	COD 31313 100 tests	COD 31014 150 tests	COD 31108 50 tests
STORE AT 2-8ºC			
Reagents for determination of RF Only for *in vitro* use in the clinical laboratory			

RHEUMATOID FACTORS (RF) - SLIDE

BioSystems
REAGENTS & INSTRUMENTS

CE

RHEUMATOID FACTORS
LATEX

PRINCIPLE OF THE METHOD

Serum rheumatoid factors (RF) causes a visible agglutination on slide of a suspension of latex particles coated with human gamma-globulin [1].

CONTENTS

	COD 31013	COD 31313	COD 31014	COD 31108
A. Reagent	1 x 3 mL	2 x 3 mL	1 x 8 mL	1 x 3 mL
C-. Negative Control	1 x 1 mL	1 x 1 mL	1 x 1 mL	-
C+. Positive Control	1 x 1 mL	1 x 1 mL	1 x 1 mL	-
Test Cards	3	6	6	-
Disposable Stirrer Sticks	1 x 50	1 x 150	1 x 150	-

COMPOSITION

A. Reagent: Suspension of latex particles coated with human gamma-globulin, sodium azide 0.95 g/L, glycine buffer 100 mmol/L, pH 8.2.

C-. Negative Control: Serum containing RF < 30 IU/mL.

C+. Positive Control: Human serum containing RF > 30 IU/mL.

Human sera used in the preparation of the positive and negative controls have been tested and found to be negative for the presence of antibodies anti-HIV and anti-HCV, as well as for HBs antigen. However, the controls should be handled cautiously as potentially infectious.

Test Cards. (Note 1)

Disposable Stirrer Sticks.

STORAGE

Store at 2-8ºC. Cards and stirrer sticks may be kept at room temperature.

Reagent and Controls are stable until the expiry date shown on the label when stored tightly closed and if contaminations are prevented during their use.

Indications of deterioration:

- Reagent: Visible agglutination in the flask.
- Controls: Presence of particulate material.

REAGENT PREPARATION

Reagent and controls are provided ready to use.

ADDITIONAL EQUIPMENT

- Mechanical rotator adjustable to 100 r.p.m.
- For code 31108 test cards and stirrer sticks will be required.

SAMPLES

Serum collected by standard procedures.

Rheumatoid factors in serum is stable for 2 days at 2-8ºC.

PROCEDURE

1. Bring test reagents and samples to room temperature (Note 2).
2. Place 50 µL of the sample and 1 drop of each Control into separate circles on the test card.
3. Shake the latex vial (A) gently repeatedly until complete resuspension of the latex particles.. Hold the Reagent vial (A) in vertical position and add 1 drop of Reagent (A) to each circle next to the sample to be tested (Note 3).
4. Mix with a disposable stirrer stick and spread over the entire area enclosed by the ring. Use a new stirrer stick for each sample.
5. Rotate cards at 100 r.p.m. for 2 minutes.

READING

Examine the presence of visible agglutinantion within a minute after removing the card from the rotator (Note 4).

Positive results: The presence of a visible agglutination indicates an RF concentration ≥ 30 IU/mL. Positive sera may be titered. To titer make serial two-fold dilutions in 9 g/L NaCl. The serum titer is defined as the highest dilution showing a positive result. The approximate RF concentration in the sample may be obtained by multiplying the titer by 8 IU/mL (Note 5).

Negative results: The absence of a visible agglutination indicates an RF concentration < 30 IU/mL.

QUALITY CONTROL

Positive (C+) and Negative (C-) Controls provided with kits should be tested toghether with the patients samples, in order to verify the assay performance.

Positive Control (C+) should cause a clear visible agglutination of the latex particles.

Negative Control (C-) should not cause any agglutination of the latex particles.

Each laboratory should establish its own internal Quality Control scheme and procedures for corrective action if controls do not recover within the acceptable tolerances.

ASSAY CHARACTERISTICS

- Detectability: 30 IU/mL RF, using an internal standard traceable to the WHO Reference Material W1066 (International Laboratory for Biological Standards, Amsterdam). The cut off value may vary up to 25% depending on uncontrolled variations in the procedure and on the operator experience in reading.
- High dose (zone) effect: False negative results due to high dose effect are absent at least up to 800 IU/mL RF.
- False results: Results obtained with this reagent did not show significative differences when compared with reference reagents. Details of the comparison experiments are available on request.
- Interferences: Hemoglobin (5 g/L), bilirubin (15 mg/dL) and lipemia (5 g/L) do not interfere. Other drugs and substances may interfere[2].

DIAGNOSTIC CHARACTERISTICS

Rheumatoid Factors (RF) are a group of IgM antibodies (although IgG and IgA have been also described) directed against the Fc fragment of the IgG molecules.

RF is mainly present in the serum of patients with rheumatoid arthritis but other diseases may also produce RF: chronic inflammatory processes, infectious diseases such as subacute bacterial endocarditis, malaria, syphilis, leprosy, leishmaniasis, tuberculosis and a variety of autoimmune diseases such as systemic lupus erythematosus[3-6].

Clinical diagnosis should not be made on the findings of a single test result, but should integrate both clinical and laboratory data.

NOTES

1. The test cards are reusable, and must be washed out and thoroughly rinsed with distilled water free of all detergents.
2. The sensitivity of the test may be reduced at low temperatures.
3. The presence of agglutinated particles at this point may be due to a lack of homogenization of the reagent.
4. Delay in reading may cause false positive results.
5. Dilution of the serum in saline causes a change in the sensitivity of the test from 30 IU/mL to 8 IU/mL due to the strong sample matrix effect on latex agglutination.

BIBLIOGRAPHY

1. Singer JM, Plotz CM. The latex fixation test: application to the serologic diagnosis of rheumatoid arthritis. *Am J Med* 1956; 21: 888-92.
2. Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000.
3. Shmerling RH, Delblanco TH. The rheumatoid factor: an analysis of clinical utility. *Am J Med* 1991; 91: 528-34
4. Sager D, Wernick RM, Davey MP. Assays for rheumatoid factor: a review of their utility and limitions in clinical practice. *Lab Med* 1992; 23: 15-8.
5. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th ed. Burtis CA, Ashwood ER, Bruns DE. WB Saunders Co, 2005.
6. Friedman and Young. Effects of disease on clinical laboratory tests, 4th ed. AACC Press, 2001.

COD 31019 50 tests	COD 31319 100 tests	COD 31086 150 tests	COD 31448 50 tests
STORE AT 2-8ºC			
Reagents for determination of ASO Only for *in vitro* use in the clinical laboratory			

ANTI-STREPTOLYSIN O (ASO) - SLIDE

CE

BioSystems
REAGENTS & INSTRUMENTS

ANTI-STREPTOLYSIN O (ASO)
LATEX

PRINCIPLE OF THE METHOD

Serum anti-streptolysin O (ASO) at 200 IU/mL or higher causes a visible agglutination on slide of a suspension of latex particles coated with streptolysin O [1].

CONTENTS

	COD 31019	COD 31319	COD 31086	COD 31448
A. Reagent	1 x 3 mL	2 x 3 mL	1 x 8 mL	1 x 3 mL
C-. Negative Control	1 x 1 mL	1 x 1 mL	1 x 1 mL	-
C+. Positive Control	1 x 1 mL	1 x 1 mL	1 x 1 mL	-
Test Cards	3	6	6	-
Disposable Stirrer Sticks	1 x 50	1 x 150	1 x 150	-

COMPOSITION

A. Reagent: Suspension of white latex particles coated with streptolysin O, sodium azide 0.95 g/L, ammonium chloride buffer 200 mmol/L, pH 8.2.

C-. Negative Control: Serum containing ASO < 200 IU/mL.

C+. Positive Control: Human serum containing ASO > 200 IU/mL.

Human sera used in the preparation of the positive and negative controls have been tested and found to be negative for the presence of antibodies anti-HIV and anti-HCV, as well as for HBs antigen. However, the controls should be handled cautiously as potentially infectious.

Test Cards. (Note 1).

Disposable Stirrer Sticks.

STORAGE

Store at 2-8ºC. Cards and stirrer sticks may be kept at room temperature.

Reagent and Controls are stable until the expiry date shown on the label when stored tightly closed and if contaminations are prevented during their use.

Indications of deterioration:

– Reagent: Visible agglutination in the flask.

– Controls: Presence of particulate material.

REAGENT PREPARATION

Reagent and controls are provided ready to use.

ADDITIONAL EQUIPMENT

– Mechanical rotator adjustable to 100 r.p.m.

– For code 31448 test cards and stirrer sticks will be required.

SAMPLES

Serum collected by standard procedures.

Anti-streptolysin O in serum is stable for 7 days at 2-8ºC.

PROCEDURE

1. Bring test reagents and samples to room temperature (Note 2).
2. Place 50 µL of the sample and 1 drop of each Control into separate circles on the test card.
3. Shake the latex vial (A) gently gently repeatedly until complete resuspension of the latex particles. Hold the Reagent vial (A) in vertical position and add 1 drop of Reagent (A) to each circle next to the sample to be tested (Note 3).
4. Mix with a disposable stirrer stick and spread over the entire area enclosed by the ring. Use a new stirrer stick for each sample.
5. Rotate cards at 100 r.p.m. for 2 minutes.

READING

Examine the presence of visible agglutinantion within a minute after removing the card from the rotator (Note 4).

Positive results: The presence of a visible agglutination indicates an ASO concentration in the sample ≥ 200 IU/mL. Positive sera may be titered. To titer make serial two-fold dilutions in 9 g/L NaCl. The serum titer is defined as the highest dilution showing a positive result. The approximate ASO concentration in the sample may be obtained by multiplying the titer by 200 IU/mL.

Negative results: The absence of a visible agglutination indicates a content of ASO < 200 IU/mL.

QUALITY CONTROL

Positive (C+) and Negative (C-) Controls provided with kits should be tested toghether with the patients samples, in order to verify the assay performance.

Positive Control (C+) should cause a clear visible agglutination of the latex particles.

Negative Control (C-) should not cause any agglutination of the latex particles.

Each laboratory should establish its own internal Quality Control scheme and procedures for corrective action if controls do not recover within the acceptable tolerances.

ASSAY CHARACTERISTICS

– Detectability: 200 IU/mL ASO, using an internal standard traceable to the Biological Reference Material 97/662 (National Institute for Biological Standards and Control, United Kingdom).The cut off value may vary up to 25% depending on uncontrolled variations in the procedure and on the operator experience in reading.

– High dose (zone) effect: False negative results due to high dose effect are absent at least up to 800 IU/mL ASO.

– False results: Results obtained with this reagent did not show significative differences when compared with reference reagents. Details of the comparison experiments are available on request.

– Interferences: Hemoglobin (5 g/L), bilirubin (15 mg/dL), rheumatoid factors (300 IU/mL) and lipemia (5 g/L) do not interfere. Other drugs and substances may interfere[3].

DIAGNOSTIC CHARACTERISTICS

Anti-streptolysin O are the specific antibodies to streptolysin O, an extracellular enzyme produced by Lancefield group A, β-hemolytic streptococci (Streptococcus pyogenes). Antibodies against streptolysin O can be detected from one week to one month after the onset of a streptococcal infection. Streptococcus pyogenes causes a wide variety of upper respiratory infections such as acute pharyngitis. Other manifestations of Streptococcus pyogenes infection include glomerulonephritis, rheumatic fever, bacterial endocarditis and scarlet fever [4-7].

Clinical diagnosis should not be made on the findings of a single test result, but should integrate both clinical and laboratory data.

NOTES

1. The test cards are reusable, and must be washed out and thoroughly rinsed with distilled water free of all detergents.
2. The sensitivity of the test may be reduced at low temperatures.
3. The presence of agglutinated particles at this point may be due to a lack of homogenization of the reagent.
4. Delay in reading may cause false positive results.

BIBLIOGRAPHY

1. Klein GC, Baker CN, Moody MD. Comparison of antistreptolysin O latex screening test with the antistreptolysin O hemolytic test. *Appl Microbiol 1970; 19:60-1.*
2. Friedman and Young. Effects of disease on clinical laboratory tests, 4th ed. AACC Press, 2001.
3. Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000.
4. Klein GC, Baker CN, Jones WL. Upper limits of normal antistreptolysin O and antideoxyribonuclease B titers. *Appl Microbiol* 1971; 21: 758-60.
5. Bisno AL. Group A streptococcal infections and acute rheumatic fever. *N Engl J Med* 1991; 325: 783-93.
6. Stevens DL. Invasive group A streptococcal disease. *Clin Infect Dis* 1992; 14: 2-11.
7. Immunology and Serology in Laboratory Medicine, 2nd edition. Turgeon ML. Mosby, 1996.

BioSystems
REAGENTS & INSTRUMENTS

EC DECLARATION OF CONFORMITY

BioSystems S.A., a company placed in Costa Brava 30, 08030 Barcelona (Spain) dedicated to the design, development and manufacturing of *in vitro* diagnostic medical devices,

Hereby DECLARES

That the products stated in the annex of five (5) pages joined herewith, meet the applicable provisions of the

Directive on in Vitro Diagnostic Medical Devices (98/79/EC)

under the specifications declared by BioSystems S.A.

It means that the products:

- complies with all applicable Essential Requirements as set out in the Annex I, and its technical documentation is performed following the requirements of the Annex III
- is classified as Other Device (all devices except Annex II and Self-Testing Devices), that is why the Conformity Assessment follows the procedure stated in the Annex III of the Directive without the intervention of a Notified Body.

Barcelona, November 6th, 2012

BioSystems
Costa Brava, 30
08030 BCN

Dr. Antonio Elduque
Managing director
BioSystems S.A.

www.tuv.com ID:9091006696
TÜVRheinland
- Certified Management System
- EN ISO 9001
- EN ISO 13485

Biosystems S.A. Costa Brava 30, 08030 Barcelona (Spain) Tel. +34-93 311 00 00 Fax +34-93 346 77 99
biosystems@biosystems.es
www.biosystems.es

CLINICAL CHEMISTRY – BIOCHEMISTRY:

a-Amylase-Direct
a-Amylase-EPS
a-Amylase-Pancreatic
Acid Phosphatase (ACP)
Alanine Aminotransferase (ALT/GPT)
Albumin
Alkaline Phosphatase (ALP)-AMP
Alkaline Phosphatase (ALP)-DEA
AspartateAminotranferase (AST/GOT)
Bilirubin (direct)
Bilirubin (total and direct)
Bilirubin (total)
Calcium – Arsenazo
Calcium – MTB
Cholesterol
Cholesterol HDL
Cholesterol HDL direct
Cholesterol HDL Precipitating reagent
Cholesterol LDL direct
Cholesterol LDL Precipitating reagent
Cholinesterase (CHE)
Citrate
Creatine Kinase (CK)
Creatine Kinase-MB (CK-MB)
Creatinine
Fructosamine
Fructose
g-Glutamyltransferase (g-GT)
Glucose
Iron – Chromazurol
Iron – Ferrozine
Iron Binding Capacity
Lactate Dehydrogenase (LDH)
Lactate Dehydrogenase (LDH) – IFCC
Lipase
Magnesium
Phosphorus
Protein (total)
Protein (urine)
Pyridoxal Phosphate
Triglycerides
Urea/BUN-Color
Urea/BUN-UV
Uric Acid

CLINICAL CHEMISTRY – TURBIDIMETRY:

a1-acid Glycoprotein
Albumin (Microalbuminuria)
Anti-Streptolysin O (ASO)
Antithrombin III
Apolipoprotein A-I (Apo A-I)
Apolipoprotein B (Apo B)
b2-Microglobulin
Complement Component C3
Complement Component C4
C-Reactive Protein (CRP)
C-Reactive Protein-hs (CRP-hs)
Ferritin
Immunoglobulin A (IgA)
Immunoglobulin G (IgG)
Immunoglobulin M (IgM)
Prealbumin
Rheumatoid Factors (RF)
Transferrin

CLINICAL CHEMISTRY – MICROCOLUMN CHROMATOGRAPHY:

17-Hydroxycorticosteroids
17-Ketosteroids
5-Aminolevulinic Acid (ALA) / Porphobilinogen (PBG)
5-Hydroxyindoleacetic acid (5-HIAA)
Hemoglobin A1C
Hemoglobin A2
Metanephrines
Vanilmandelic Acid

CLINICAL CHEMISTRY – STANDARDS and CALIBRATORS:

a-1-acid Glycoprotein Standard
Adenosine Deaminase (ADA) Standard
Albumin (Microalbuminuria) Standard
Anti-Streptolysin O (ASO) Standard
Antithrombin III Standard
Apolipoprotein A-I Standard
Apolipoprotein B Standard
b2-Microglobulin Standard
Bilirubin Standard
Biochemistry Calibrator
Biochemistry Calibrator (Human)
Cholesterol HDL/LDL Calibrator
CRP/CRP-hs Standard
Ferritin Standard
Hemoglobin A1C-Turbi (HbA1C-Turbi) Standard
Prealbumin Standard
Protein Calibrators
Protein (urine) Standard
Rheumatoid Factors (RF) Standard

CLINICAL CHEMISTRY – INSTRUMENTS:

A15
A25
BA400
BTS-350

CLINICAL CHEMISTRY – BIOCHEMISTRY – REAGENTS AUTOMATED SYSTEMS:

a-Amylase-Direct
a-Amylase-Pancreatic
Adenosine Deaminase (ADA)
Alanine Aminotransferase (ALT/GPT)
Albumin
Alkaline Phosphatase (ALP)-AMP
Alkaline Phosphatase (ALP)-DEA
Aspartate Aminotransferase (AST/GOT)
Bilirubin (direct)
Bilirubin (total)
Calcium-Arsenazo
Cholesterol
Cholesterol HDL direct
Cholesterol LDL direct
Creatine Kinase (CK)
Creatine Kinase-MB (CK-MB)
Creatinine
g-Glutamyltransferase (g-GT)
Glucose
Iron Ferrozine
Lactate dehydrogenase (LDH)
Lipase
Magnesium
Phosphorus
Protein (total)
Protein (urine)
Triglycerides
Urea/BUN UV
Uric acid

CLINICAL CHEMISTRY – TURBIDIMETRY – REAGENTS AUTOMATED SYSTEMS:

Albumin (Microalbuminuria)
Anti-Streptolysin O (ASO)
Antithrombin III
Complement Component C3
Complement Component C4
C-Reactive Protein (CRP)
C-Reactive Protein-hs (CRP-hs)
Ferritin
Hemoglobin A1C-Turbi (HbA1C-Turbi)
Immunoglobulin A (IgA)
Immunoglobulin G (IgG)
Immunoglobulin M (IgM)
Rheumatoid Factors (RF)
Transferrin

CLINICAL CHEMISTRY – INTERNAL QUALITY CONTROL:

ADA Controls
Biochemistry Control Serum (Human) I
Biochemistry Control Serum (Human) II
Biochemistry Control Serum I
Biochemistry Control Serum II
CK-MB Control Serum
Control Urine
Fertility Biochemistry Control
Hemoglobin A1C Control (Elevated)
Hemoglobin A1C Control (Normal)
Hemoglobin A2 Control
Lipid Control Serum I
Lipid Control Serum II
Protein Control Serum I
Protein Control Serum II
Rheumatoid Control Serum I
Rheumatoid Control Serum II

AUTOIMMUNITY – IFA (IMMUNOFLUORESCENCE):

Anti-Adrenal Cortex Antibodies (AACA)
Anti-Endomysium Antibodies (AEA)
Anti-Islet Cell Antibodies (AICA)
Anti-Keratin Antibodies (AKA)
Anti-Mitochondrial Antibodies (AMA)
Anti-nDNA antibodies (nDNA)
Anti-Neutrophil Cytoplasmic Antibodies (ANCA)
Anti-Nuclear Antibodies HEp-2 (ANA HEp-2)
Anti-Nuclear Antibodies RL (ANA-RL)
Anti-Skin Antibodies (ASA)
Anti-Smooth Muscle Antibodies (ASMA)
Anti-Striated Muscle Antibodies (AStMA)
Anti-Thyroid Antibodies (ATA)
Autoantibodies DUO-HEp2/ML (DUO-HEp2/ML)
Autoantibodies MsK/MsS (AA-MsK/MsS)
Autoantibodies MsL/MsK/MsS (AA-MsL/MsK/MsS)
Autoantibodies RK/RS (AA-RK/RS)
Autoantibodies RL/RK/RS (AA-RL/RK/RS)
Autoantibodies RL/RKm/RS (AA-RL/RKm/RS)
Glomerular Basement Membrane Antibodies (GBMA)

AUTOIMMUNITY – ELISA:

ANA Screening
Anti-Annexin V IgG/IgM (ANX)
Anti-b2-Glycoprotein 1 IgG/IgM (b2GP1)
Anti-Cardiolipin Antibodies (ACA-IgG/IgM)
Anti-Centromere B Antibodies (CENP-B)
Anti-Citrullinated Protein Antibodies (ACPA)
Anti-Deamidated Gliadin Peptides IgA (DGP IgA)
Anti-Deamidated Gliadin Peptides IgG (DGP IgG)
Anti-dsDNA Antibodies
Anti-GBM Antibodies - EIA (GBM)
Anti-Gliadin Antibodies (AGA-IgG/IgA)
Anti-Histones Antibodies (HIST)
Anti-Insulin Antibodies (INS)
Anti-Jo1 Antibodies
Anti-M2 Antibodies (M2)
Anti-MPO Antibodies
Anti-Nucleosome Antibodies (NCL)
Anti-Phospholipid IgG/IgM (APLA)
Anti-PR3 Antibodies
Anti-Ribosomal P Antibodies (Rib P)
Anti-Scl70 Antibodies
Anti-Sm Antibodies
Anti-Sm/RNP Antibodies
Anti-SSA (Ro) Antibodies
Anti-SSB (La) Antibodies
Anti-Thyroglobulin Antibodies (Anti-Tg)
Anti-Thyroid Peroxidase Antibodies (Anti-TPO)
Anti-tTransglutaminase IgA Antibodies (Anti- tTG IgA)
Anti-tTransglutaminase IgG Antibodies (Anti- tTG IgG)
ASCA-IgG/IgA (ASCA)
ENA 4-Profile
ENA 6-Screening

AUTOINMUNIDAD – INSTRUMENTOS:
AUTOIMMUNITY – INSTRUMENTS:

iPRO

RAPID TESTS – LATEX AGGLUTINATION:

Anti-Streptolysin O (ASO) - Slide
C-Reactive Protein (CRP) - Slide
Rheumatoid factors (RF) - Slide

INFECTIOUS IMMUNOLOGY – SYPHILIS:

RPR-Carbon
TPHA

INFECTIOUS IMMUNOLOGY – FEBRILE ANTIGENS:

Febrile Serodiagnostics Multiscreening
Febrile Serodiagnostics Salmonella
Brucella abortus
Brucella abortus, Rose Bengal
Proteus Ox19
Salmonella paratyphi AH
Salmonella paratyphi AO
Salmonella paratyphi BH
Salmonella paratyphi BO
Salmonella paratyphi CH
Salmonella paratyphi CO
Salmonella typhi H
Salmonella typhi O
Brucella Positive Control
Proteus Positive Control
Salmonella Positive Control
Serology Negative Control

Certificate

Standard **ISO 9001:2015**

Certificate Registr. No. **01 100 6696**

Certificate Holder:

BIOSYSTEMS S.A.
Costa Brava 30
08030 Barcelona
Spain

Scope:

Design, development, manufacture, distribution, servicing of:
-Instruments and reagents for clinical diagnostic.
-Instruments and reagents for agro-alimentary analysis.
Distribution and service of reagents and instruments for veterinary diagnosis.

Proof has been furnished by means of an audit that the requirements of ISO 9001:2015 are met.

Validity:

The certificate is valid from 2019-12-19 until 2022-12-18.
First certification 1996

2019-12-20

TÜV Rheinland Cert GmbH
Am Grauen Stein · 51105 Köln

Annex to certificate

Standard **ISO 9001:2015**

Certificate Registr. No. **01 100 6696**

No.	Location	Scope
/02	BIOSYSTEMS S.A. Pol. Ind. Can Tapioles naus 7-12-13 08110 Montcada i Reixac Spain	Labeling and assembly of reagent. Storage, and shipping of: - Instruments and reagents for diagnosis and reagents for clinical diagnosis.- Instruments and reagents for agri-food analysis.- Instruments and reagents for veterinary diagnosis.

2019-12-20

TÜV Rheinland Cert GmbH
Am Grauen Stein · 51105 Köln

TÜVRheinland®

Certificate

The Certification Body of
TÜV Rheinland LGA Products GmbH

hereby certifies that the organization

BIOSYSTEMS S.A.
Costa Brava 30
08030 Barcelona
Spain

has established and applies a quality management system for medical devices for the following scope:

Design and development, manufacture, distribution and servicing of instruments and reagents for clinical diagnostic
(see attachment for sites included)

Proof has been furnished that the requirements specified in

EN ISO 13485:2016

are fulfilled. The quality management system is subject to yearly surveillance.

Effective Date:	2020-01-08
Certificate Registration No.:	SX 60145545 0001
An audit was performed. Report No.:	28300434 004
This Certificate is valid until:	2022-12-12

Certification Body

DAkkS
Deutsche
Akkreditierungsstelle
D-ZM-14169-01-02

TÜV Rheinland LGA Products GmbH
TÜVRheinland®
Zertifizierungsstelle

Date 2020-01-08

D. Swiatko

TÜV Rheinland LGA Products GmbH - Tillystraße 2 - 90431 Nürnberg
Tel.: +49 221 806-1371 Fax: +49 221 806-3935 e-mail:cert-validity@de.tuv.com http://www.tuv.com/safety

TÜVRheinland®

Doc. 1/1, Rev. 0

TÜV Rheinland
LGA Products GmbH
Tillystraße 2, 90431 Nürnberg

Attachment to Certificate Registration No.: SX 60145545 0001
Report No.: 28300434 004

Organization:
BIOSYSTEMS S.A.
Costa Brava 30
08030 Barcelona
Spain

Scope:

Site included:

Polígono Industrial Can Tapioles
Naves 7, 12 y 13
08110 Montcada i Reixac
Spain

Activity: Labelling and assembling of reagents, warehousing and shipment of instruments and reagents for clinical diagnostic

Certification Body

DAkkS
Deutsche Akkreditierungsstelle
D-ZM-14169-01-02

TÜV Rheinland LGA Products GmbH TÜVRheinland® Zertifizierungsstelle

Date: 2020-01-08

D. Swiatko